Chemistry Reference
In-Depth Information
43. Marasini, N., Tran, T.H., Poudel, B.K., Cho, H.J., Choi, Y.K., Chi, S.-C., Choi, H.-G., Yong,
C.S., and Kim, J.O. (2013) Fabrication and evaluation of pH-modulated solid dispersion for
telmisartan by spray-drying technique.
Int. J. Pharm.
, 441:424-432.
44. Soliman, O.A.E., Kimura, K., Hirayama, F., Uekama, K., El-Sabbagh, H.M., El-Gawad,
A.E.H., and Hashim, F.M. (1997) Amorphous spironolactone-hydroxypropylated cyclo-
dextrin complexes with superior dissolution and oral bioavailability.
Int. J. Pharm.
, 149:
73
83.
45. Nagarsenkar, M.S., Meshram, R.N., and Ramprakash, G. (2000) Solid dispersion of hydrox-
ypropyl
β
-cyclodextrin and ketorolac: enhancement of
in-vitro
dissolution rates, improvement
in anti-inflammatory activity and reduction in ulcerogenicity in rats.
J. Pharm. Pharmacol.
,
52:949-956.
46. Mora, P.C., Cirri, M., Allolio, B., Carli, F., and Mura, P. (2003) Enhancement of dehydro-
epiandrosterone solubility and bioavailability by ternary complexation with
α
-cyclodextrin
and glycine.
J. Pharm. Sci.
, 92:2177-2184.
47. Law, S.L, Lo, W.Y, Lin, F.M., and Chaing, C.H. (1992) Dissolution and absorption of
nifedipine in polyethylene glycol solid dispersions containing phosphatidylcholine.
Int.
J. Pharm.
, 84:161-166.
48. Khoo, S.-M., Porter, C.J.H., and Charman, W.N. (2000) The formulation of halofantrine as
either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: physical
stability and absolute bioavailability assessment.
Int. J. Pharm.
, 205:65-78.
49. Unga, J., Matsson, P., and Mahlin, D. (2010) Understanding polymer-lipid solid dispersions:
the properties of incorporated lipids govern the crystallization of PEG.
Int. J. Pharm.
,
386:61-70.
50. Lobmann, K., Grohganz, H., Laitinen, R., Strachan, C., and Rades, T. (2013) Amino acids as
co-amorphous stabilizers for poorly water soluble drugs—part I: preparation, stability, and
dissolution enhancement.
Eur. J. Pharm.
, 85(3):873-881.
51. Lobmann, K., Laitinen, R., Strachan, C., Rades, T., and Grohganz, H. (2013) Amino acids
as co-amorphous stabilizers for poorly water soluble drugs—part II: molecular interactions.
Eur. J. Pharm. Biopharm.
, 85(3):882-888.
52. Pan, R.-N., Chen, J.-H., and Chen, R.R. (2000) Enhancement of dissolution and bioavailability
of piroxicam in solid dispersion systems.
Drug Dev. Ind. Pharm.
, 26(9):989
-
994.
53. Lu, Q. and Zografi, G. (1998) Phase behavior of binary and ternary amorphous mixtures
containing indomethacin, citric acid, and PVP.
Pharm. Res.
, 15(8):1202-1206.
54. Matsumoto, T. and Zografi, G. (1999) Physical properties of solid molecular dispersions of
indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-
co
-vinyl-acetate) in
relation to indomethacin crystallization.
Pharm. Res.
, 16(11):1722-1728.
55. Yang, J., Grey, K., and Doney, J. (2010) An improved kinetics approach to describe the
physical stability of amorphous solid dispersions.
Int. J. Pharm.
, 384:24-31.
56. Newman, A. (2013) Specialized solid form screening techniques.
Org. Process Res. Dev.
,
17:457-471.
57. Keen, J.M., McGinity, J.W., and Williams, R.O., III (2013) Enhancing bioavailability through
thermal processing.
Int. J. Pharm.
, 450(1-2):185-196.
58. Forster, A., Hempenstall, J., Tucker, I., and Rades, T. (2001) The potential of small-scale
fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer
blends for melt extrusion.
Drug Dev. Ind. Pharm.
, 27(6):549-560.
-
